Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for BMY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1996. Start Trial.
Date Value
June 30, 2026 3.393B
March 31, 2026 1.104B
December 31, 2025 1.974B
September 30, 2025 6.311B
June 30, 2025 3.917B
March 31, 2025 1.954B
December 31, 2024 4.439B
September 30, 2024 5.591B
June 30, 2024 2.326B
March 31, 2024 2.834B
December 31, 2023 4.252B
September 30, 2023 4.751B
June 30, 2023 1.887B
March 31, 2023 2.97B
December 31, 2022 3.306B
September 30, 2022 3.687B
June 30, 2022 2.261B
March 31, 2022 3.812B
December 31, 2021 4.057B
September 30, 2021 5.266B
June 30, 2021 3.06B
March 31, 2021 3.824B
December 31, 2020 3.67B
September 30, 2020 2.219B
June 30, 2020 4.269B
Date Value
March 31, 2020 3.894B
December 31, 2019 2.038B
September 30, 2019 2.556B
June 30, 2019 2.083B
March 31, 2019 1.39B
December 31, 2018 2.429B
September 30, 2018 1.279B
June 30, 2018 1.057B
March 31, 2018 1.175B
December 31, 2017 1.117B
September 30, 2017 1.713B
June 30, 2017 1.584B
March 31, 2017 861.00M
December 31, 2016 1.428B
September 30, 2016 1.397B
June 30, 2016 411.00M
March 31, 2016 -386.00M
December 31, 2015 611.00M
September 30, 2015 524.00M
June 30, 2015 71.00M
March 31, 2015 626.00M
December 31, 2014 572.00M
September 30, 2014 903.00M
June 30, 2014 1.056B
March 31, 2014 617.00M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 8.616B
Eli Lilly & Co. 10.69B
Merck & Co., Inc. 5.37B
Pfizer Inc. 835.00M
AstraZeneca PLC 3.420B